HIMS Faces Negative Impact from FDA's Peptide Recommendation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: Newsfilter
- FDA Recommendation Impact: HIMS is facing negative repercussions due to the FDA's recommendation against adding seven peptides to the bulk list, which will limit product diversity and potentially weaken market competitiveness, hindering future revenue growth.
- Market Reaction: The FDA's decision may adversely affect HIMS's peptide product line, raising investor concerns about the company's future profitability and potentially leading to stock price volatility.
- Analyst Rating Adjustment: Despite these challenges, BofA has raised HIMS's price target to $36, indicating confidence in the company's long-term potential, which may attract some investors to reassess their investment strategies.
- Strategic Adjustment Necessity: HIMS must reevaluate its product portfolio and market strategy in response to the FDA's restrictions to ensure sustained growth and innovation capabilities in a highly competitive market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to fall
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 38.280
Low
16.50
Averages
32.95
High
60.00
Current: 38.280
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HIMS CEO Emphasizes Long-Term Execution Amid Stock Volatility
- Stock Moves Unrelated to Business: HIMS CEO Andrew Dudum stated that stock volatility is disconnected from the company's fundamentals, noting an 8% rise last week, but emphasized that the real test lies in patient impact and profitability.
- Public Listing as Boot Camp: Dudum defended HIMS' early public listing as a 'boot camp' that forced the company to balance quarterly execution with long-term vision, thereby enhancing operational discipline.
- Patient Scale and Market Potential: HIMS serves 10,000 to 15,000 patients daily, with Dudum suggesting this could represent the largest healthcare system globally, despite the company being in its early innings of growth.
- Future Vision and Industry Standard: Dudum aims for HIMS to become the 'gold standard' in healthcare over the next decade, planning to build a platform around proactive care, advanced diagnostics, and wearables to address various clinical needs.
See More
Investment Choices: Hims & Hers vs. Teladoc
- User Growth Surge: Hims & Hers Health boasts nearly 2.6 million subscribers as of Q1 2026, indicating significant market traction for its direct-to-consumer wellness solutions, thereby enhancing its competitive position in the digital health sector.
- Financial Performance Comparison: Hims & Hers reported nearly $2.3 billion in revenue for FY 2025, reflecting a robust 59% year-over-year growth, while Teladoc's revenue of approximately $2.5 billion saw a slight decline of 1.5%, suggesting Hims & Hers may attract investors seeking rapid growth.
- Market Risks and Regulatory Pressures: Hims & Hers faces regulatory scrutiny from the FDA regarding compounded GLP-1s and potential DOJ investigations, which could hinder its growth trajectory, whereas Teladoc's heavy customer concentration poses risks of significant financial impact from losing major clients.
- Valuation and Investment Strategy: Hims & Hers carries a premium valuation due to its growth potential, raising investor concerns over regulatory issues, while Teladoc's lower P/S ratio and turnaround strategy appeal to those looking for opportunities in undervalued stocks.
See More
Investment Comparison Between Hims & Hers and Teladoc
- User Base Growth: As of Q1 2026, Hims & Hers boasts approximately 2.6 million subscribers, reflecting significant growth and indicating strong market acceptance of its direct-to-consumer health solutions, thereby enhancing its competitive position in the digital health sector.
- Financial Performance Comparison: Hims & Hers reported nearly $2.3 billion in revenue for FY 2025, representing a robust 59% year-over-year growth, while Teladoc's revenue of $2.5 billion saw a slight decline of 1.5%, highlighting Hims & Hers' stronger performance in profitability and market demand.
- Acquisition and Financing Dynamics: Hims & Hers is scaling operations through the acquisition of Eucalyptus and has secured a $400 million receivables facility with JPMorgan Chase, which will support its pharmacy operations and further solidify its market position.
- Risks and Challenges: Hims & Hers faces potential FDA restrictions on certain ingredients and investigations by the DOJ and HHS, while Teladoc's heavy reliance on a few large clients poses a risk to its financial stability, illustrating the significant strategic differences between the two companies.
See More
United Therapeutics Corp Sees Surge in Options Trading Volume
- Surge in Options Volume: United Therapeutics Corp (UTHR) recorded an options trading volume of 3,201 contracts today, equating to approximately 320,100 shares, which represents 53.6% of its average daily trading volume of 597,710 shares over the past month.
- High Demand Options: Notably, the $590 strike call option has seen 3,151 contracts traded today, representing around 315,100 underlying shares, indicating strong market expectations for the stock's future appreciation.
- Hims & Hers Performance: Hims & Hers Health Inc (HIMS) has reported an options trading volume of 94,774 contracts today, translating to approximately 9.5 million shares, which accounts for 48.8% of its average daily trading volume of 19.4 million shares over the past month, reflecting investor interest in its future performance.
- High Strike Demand: The $40 strike call option for HIMS has seen 13,084 contracts traded today, representing about 1.3 million underlying shares, suggesting market confidence in the company's growth prospects.
See More
Hims & Hers Secures $400M Financing Agreement with JPMorgan Chase
- Financing Agreement Secured: Hims & Hers units XeCare and Apostrophe Pharmacy entered into a $400 million receivables purchase agreement with JPMorgan Chase, allowing the company to obtain immediate cash by selling customer receivables, thereby enhancing liquidity for its healthcare and pharmacy operations.
- Price Target Increases: Bank of America raised Hims' price target from $25 to $36 while maintaining a 'Neutral' rating, noting solid early traction for its branded GLP-1 products, although it remains to be seen if the company can sustain enough subscribers to support future EBITDA growth.
- Market Sentiment Shift: Retail sentiment for Hims on Stocktwits remains 'bearish', yet message volume surged by 177% in 24 hours, indicating increased investor interest and discussion regarding the company's new financing agreement, which may reflect a positive market reaction.
- FDA Regulatory Challenges: Hims' peptide products face FDA scrutiny, with analysts suggesting that the preliminary recommendation is not a final rejection, maintaining an optimistic outlook on future approvals, which could significantly impact the company's market prospects and investor confidence.
See More
FDA Revives Advisory Committee Meetings for Drug Approvals
- Advisory Committee Revival: The FDA is reviving its Advisory Committee meetings under new leadership to reassess controversial decisions made during Marty Makary's tenure, which is expected to enhance the transparency and scientific rigor of drug approvals.
- Replimune and Capricor Reviews: Replimune (REPL) and Capricor Therapeutics (CAPR) are set for FDA advisory committee reviews at the end of July, with Replimune's RP1 targeting melanoma and Capricor's Deramiocel aimed at Duchenne muscular dystrophy, potentially impacting their market performance.
- Moderna Vaccine Endorsement: Moderna (MRNA) has received unanimous backing from the FDA's Vaccines Advisory Committee for its flu vaccine mRNA-1010, currently under review with a target action date of August 5, indicating strong competitive positioning in the vaccine market.
- Hims & Hers Market Potential: Hims & Hers Health (HIMS) is expected to benefit from an upcoming advisory committee meeting, which could allow it to capture one-fifth of the telehealth peptide market projected to reach $2.2 billion by 2027, although market performance remains uncertain.
See More
HIMS CEO Emphasizes Long-Term Execution Amid Stock Volatility
- Stock Moves Unrelated to Business: HIMS CEO Andrew Dudum stated that stock volatility is disconnected from the company's fundamentals, noting an 8% rise last week, but emphasized that the real test lies in patient impact and profitability.
- Public Listing as Boot Camp: Dudum defended HIMS' early public listing as a 'boot camp' that forced the company to balance quarterly execution with long-term vision, thereby enhancing operational discipline.
- Patient Scale and Market Potential: HIMS serves 10,000 to 15,000 patients daily, with Dudum suggesting this could represent the largest healthcare system globally, despite the company being in its early innings of growth.
- Future Vision and Industry Standard: Dudum aims for HIMS to become the 'gold standard' in healthcare over the next decade, planning to build a platform around proactive care, advanced diagnostics, and wearables to address various clinical needs.
See More
Investment Choices: Hims & Hers vs. Teladoc
- User Growth Surge: Hims & Hers Health boasts nearly 2.6 million subscribers as of Q1 2026, indicating significant market traction for its direct-to-consumer wellness solutions, thereby enhancing its competitive position in the digital health sector.
- Financial Performance Comparison: Hims & Hers reported nearly $2.3 billion in revenue for FY 2025, reflecting a robust 59% year-over-year growth, while Teladoc's revenue of approximately $2.5 billion saw a slight decline of 1.5%, suggesting Hims & Hers may attract investors seeking rapid growth.
- Market Risks and Regulatory Pressures: Hims & Hers faces regulatory scrutiny from the FDA regarding compounded GLP-1s and potential DOJ investigations, which could hinder its growth trajectory, whereas Teladoc's heavy customer concentration poses risks of significant financial impact from losing major clients.
- Valuation and Investment Strategy: Hims & Hers carries a premium valuation due to its growth potential, raising investor concerns over regulatory issues, while Teladoc's lower P/S ratio and turnaround strategy appeal to those looking for opportunities in undervalued stocks.
See More
Investment Comparison Between Hims & Hers and Teladoc
- User Base Growth: As of Q1 2026, Hims & Hers boasts approximately 2.6 million subscribers, reflecting significant growth and indicating strong market acceptance of its direct-to-consumer health solutions, thereby enhancing its competitive position in the digital health sector.
- Financial Performance Comparison: Hims & Hers reported nearly $2.3 billion in revenue for FY 2025, representing a robust 59% year-over-year growth, while Teladoc's revenue of $2.5 billion saw a slight decline of 1.5%, highlighting Hims & Hers' stronger performance in profitability and market demand.
- Acquisition and Financing Dynamics: Hims & Hers is scaling operations through the acquisition of Eucalyptus and has secured a $400 million receivables facility with JPMorgan Chase, which will support its pharmacy operations and further solidify its market position.
- Risks and Challenges: Hims & Hers faces potential FDA restrictions on certain ingredients and investigations by the DOJ and HHS, while Teladoc's heavy reliance on a few large clients poses a risk to its financial stability, illustrating the significant strategic differences between the two companies.
See More
United Therapeutics Corp Sees Surge in Options Trading Volume
- Surge in Options Volume: United Therapeutics Corp (UTHR) recorded an options trading volume of 3,201 contracts today, equating to approximately 320,100 shares, which represents 53.6% of its average daily trading volume of 597,710 shares over the past month.
- High Demand Options: Notably, the $590 strike call option has seen 3,151 contracts traded today, representing around 315,100 underlying shares, indicating strong market expectations for the stock's future appreciation.
- Hims & Hers Performance: Hims & Hers Health Inc (HIMS) has reported an options trading volume of 94,774 contracts today, translating to approximately 9.5 million shares, which accounts for 48.8% of its average daily trading volume of 19.4 million shares over the past month, reflecting investor interest in its future performance.
- High Strike Demand: The $40 strike call option for HIMS has seen 13,084 contracts traded today, representing about 1.3 million underlying shares, suggesting market confidence in the company's growth prospects.
See More
Hims & Hers Secures $400M Financing Agreement with JPMorgan Chase
- Financing Agreement Secured: Hims & Hers units XeCare and Apostrophe Pharmacy entered into a $400 million receivables purchase agreement with JPMorgan Chase, allowing the company to obtain immediate cash by selling customer receivables, thereby enhancing liquidity for its healthcare and pharmacy operations.
- Price Target Increases: Bank of America raised Hims' price target from $25 to $36 while maintaining a 'Neutral' rating, noting solid early traction for its branded GLP-1 products, although it remains to be seen if the company can sustain enough subscribers to support future EBITDA growth.
- Market Sentiment Shift: Retail sentiment for Hims on Stocktwits remains 'bearish', yet message volume surged by 177% in 24 hours, indicating increased investor interest and discussion regarding the company's new financing agreement, which may reflect a positive market reaction.
- FDA Regulatory Challenges: Hims' peptide products face FDA scrutiny, with analysts suggesting that the preliminary recommendation is not a final rejection, maintaining an optimistic outlook on future approvals, which could significantly impact the company's market prospects and investor confidence.
See More
FDA Revives Advisory Committee Meetings for Drug Approvals
- Advisory Committee Revival: The FDA is reviving its Advisory Committee meetings under new leadership to reassess controversial decisions made during Marty Makary's tenure, which is expected to enhance the transparency and scientific rigor of drug approvals.
- Replimune and Capricor Reviews: Replimune (REPL) and Capricor Therapeutics (CAPR) are set for FDA advisory committee reviews at the end of July, with Replimune's RP1 targeting melanoma and Capricor's Deramiocel aimed at Duchenne muscular dystrophy, potentially impacting their market performance.
- Moderna Vaccine Endorsement: Moderna (MRNA) has received unanimous backing from the FDA's Vaccines Advisory Committee for its flu vaccine mRNA-1010, currently under review with a target action date of August 5, indicating strong competitive positioning in the vaccine market.
- Hims & Hers Market Potential: Hims & Hers Health (HIMS) is expected to benefit from an upcoming advisory committee meeting, which could allow it to capture one-fifth of the telehealth peptide market projected to reach $2.2 billion by 2027, although market performance remains uncertain.
See More
